Find information on thousands of medical conditions and prescription drugs.

Multiple system atrophy

Multiple system atrophy (MSA) is a degenerative neurological disorder characterized by a combination of the following: more...

Mac Ardle disease
Macular degeneration
Mad cow disease
Maghazaji syndrome
Mal de debarquement
Malignant hyperthermia
Mallory-Weiss syndrome
Malouf syndrome
Marburg fever
Marfan syndrome
MASA syndrome
Mast cell disease
MAT deficiency
Maturity onset diabetes...
McArdle disease
McCune-Albright syndrome
Mediterranean fever
Megaloblastic anemia
Meleda Disease
Meniere's disease
Mental retardation
Mercury (element)
Metabolic acidosis
Metabolic disorder
Methylmalonic acidemia
Microscopic polyangiitis
Microtia, meatal atresia...
Miller-Dieker syndrome
Mitochondrial Diseases
Mitral valve prolapse
Mobius syndrome
MODY syndrome
Moebius syndrome
Molluscum contagiosum
MOMO syndrome
Mondini Dysplasia
Mondor's disease
Monoclonal gammopathy of...
Morquio syndrome
Motor neuron disease
Moyamoya disease
MPO deficiency
Mullerian agenesis
Multiple chemical...
Multiple endocrine...
Multiple hereditary...
Multiple myeloma
Multiple organ failure
Multiple sclerosis
Multiple system atrophy
Muscular dystrophy
Myalgic encephalomyelitis
Myasthenia gravis
Mycosis fungoides
Myelodysplastic syndromes
Myeloperoxidase deficiency
Myoadenylate deaminase...
Myositis ossificans
  • Progressive damage to the nervous system, leading to low blood pressure when standing, difficulty urinating, and abnormal breathing during sleep
  • Muscle tremor and rigidity (Parkinsonism)
  • Slow movement (ataxia)

When autonomic failure predominates, the term Shy-Drager Syndrome is often used.

MSA is associated with the degeneration of nerve cells in specific areas of the brain. This cell degeneration causes problems with movement, balance and automatic functions of the body such as bladder control.

Nerve cells in the affected areas of the brain shrink (atrophy). When brain tissue of a person with MSA is examined under a microscope, structures called glial inclusion bodies can be seen. It is the presence of these inclusion bodies in the movement, balance and automatic control centres of the brain that confirms a diagnosis of MSA.


For men, the first sign is often erectile dysfunction (unable to achieve or sustain an erection). Both men and women often experience problems with their bladders including urgency, frequency, incomplete bladder emptying or an inability to pass urine.

As the disease progresses three groups of symptoms predominate. These are:

  • parkinsonism (slow, stiff movement, writing becomes small and spidery)
  • cerebellar (co-ordinating movement and balance)
  • autonomic (automatic body functions) including:
— postural or orthostatic hypotension, resulting in dizziness or fainting when standing up
— urinary incontinence
— impotence
— dry mouth and skin
— trouble regulating body temperature due to abnormal sweating
— breathing difficulties

Not all patients experience all of these symptoms.


MSA usually progresses more quicly than Parkinsons disease (Bower, 1997). Almost 80% of patients are disabled within 5 years of onset of the motor symptoms, and only 20% survive past 12 years. The mean survival is roughly 6 years. Rate of progression differs in every case and speed of decline may vary widely in individual patients.


There is no cure for MSA, so treatment involves treating the symptoms.

One particularly serious problem (the drop in blood pressure on standing up) often responds to fludrocortisone, a synthetic mineralocorticoid.

Levdopa (L-DOPA) does not alleviate the symtops of most MSA patients. In fact, poor response to Levdopa has been suggested as a possible element in the differential diagnosis of MSA from Parkinson's Disease.


Other terms have been used to refer to this disorder, based on the predominant systems presented. These terms and their distinctions have been dropped in recent (1996 onwards) medical usage, but are helpful to understanding the older literature about this disease:


[List your site here Free!]

Spinal Muscular Atrophy Type 1 - )
From CHEST, 4/1/00 by John R. Bach

A Noninvasive Respiratory Management Approach

Study objective: To determine whether spinal muscular atrophy (SMA) type 1 can be managed without tracheostomy and to compare extubation outcomes using a respiratory muscle aid protocol vs conventional management.

Design: A retrospective cohort study.

Methods: Eleven SMA type 1 children were studied during episodes of respiratory failure. Nine children required multiple intubations. Along with standard treatments, these children received manually and mechanically assisted coughing to reverse airway mucus-associated decreases in oxyhemoglobin saturation. Extubation was not attempted until, most importantly, there was no oxygen requirement to maintain oxyhemoglobin saturation greater than 94%. After extubation, all patients received nasal ventilation with positive end-expiratory pressure. Successful extubation was defined by no need to reintubate during the current hospitalization.

Results: Two children have survived for 37 and 66 months and have never been intubated despite requiring 24-h nasal ventilation since 5 and 7 months of age, respectively. One other child underwent tracheostomy for persistent left lung collapse and inadequate home care, another for need for frequent readmission and intubation, and one child was lost to follow-up 3 months after successful extubation. The other six children have been managed at home for 15 to 59 (mean 30.4) months using nocturnal nasal ventilation after an episode of respiratory failure. The nine children were successfully extubated by our protocol 23 of 28 times. The same children managed conventionally were successfully extubated 2 of 20 times when not using this protocol (p [is less than] 0.001 by the two-tailed Fisher's Exact t Test).

Conclusion: Although intercurrent chest colds may necessitate periods of hospitalization and intubation, tracheostomy can be avoided throughout early childhood for some children with SMA type 1.

(CHEST 2000; 117:1100-1105)

Key words: bilevel positive airway pressure; mechanical ventilation; noninvasive ventilation; pulmonary complications; respiratory failure; spinal muscular atrophy; survival

Abbreviations: EPAP = expiratory positive airway pressure; IPAP = inspiratory positive airway pressure; MI-E = mechanical insufflation-exsufflation; Sa[O.sub.2] = arterial oxyhemoglobin saturation; SMA = spinal muscular atrophy

Autosomal recessive spinal muscular atrophy (SMA) is the most common inherited neuromuscular disease of the hypotonic newborn and, along with Duchenne muscular dystrophy, is 1 of the 2 most commonly inherited neuromuscular diseases. It is caused by a chromosome 5 defect. About 1 in 40 people carry the defective gene, and the overall incidence has been reported to be 1 out of 5000.[1] It has been categorized into 4 types according to severity. The SMA type 1 infant never attains the ability to sit independently. Less than 20% of these children survive 4 years, and then only with indwelling tracheostomy tubes.[2] Virtually all die from respiratory complications. SMA type 2 children can temporarily sit independently but can never walk, and they too usually have periods of respiratory failure during early childhood. Other SMA types have milder courses.

The lungs of patients with neuromuscular disease can be ventilated noninvasively by intermittent positive pressure ventilation provided by volume-cycled ventilators or by pressure-cycled ventilators. However, with or without using ventilatory assistance,[3-5] SMA patients are usually stable until an intercurrent chest cold results in pneumonia and acute respiratory failure because of inability to cough effectively.[6] For SMA type 1 infants this usually occurs between birth and 2 1/2 years of age. Clinicians are often reluctant to intubate them because they often lose breathing autonomy with the correction of compensatory metabolic alkalosis that accompanies normalization of arterial carbon dioxide tensions.

Further, once a patient is intubated, tracheostomy is thought to be mandatory when ventilator weaning is delayed or thought to be impossible. Because it is considered inevitable, tracheostomy is often recommended during the initial episode of respiratory failure.[3] If these infants wean from ventilator use, are extubated, and the parents persist in refusing tracheostomy, the parents are often advised to avoid future intubations and to simply let the children die.[3]

Because we have succeeded in using continuous noninvasive ventilation long-term as an alternative to tracheostomy,[6-8] and because we have used a home respiratory muscle aid protocol to avoid pneumonias and hospitalizations for older patients who can cooperate,[9] when parents refused tracheostomies for their infants, we attempted to modify this protocol for their children.[9] We hypothesized that we could use these principles for hospitalized SMA type 1 children who require endotracheal intubation for episodes of respiratory failure and thereby maintain the children free of tracheostomy until they are old enough to cooperate fully with the home protocol. In this way it may be possible to avert tracheostomy indefinitely.[9] We also hypothesized that extubation would more likely be successful for patients managed by our protocol than for patients managed conventionally.


Eleven consecutively referred SMA type 1 children in respiratory, failure were managed as per a protocol (Table 1) that was approved by our Institutional Review Board. All 11 patients had severe skeletal and bulbar muscle weakness to the extent that none had functional extremity movements or ability to take any nutrition by mouth. Three have not developed the ability to verbalize. All of the parents of the 11 had refused tracheostomies on multiple occasions.

Table 1--Protocol vs Conventional Management of Intubated SMA 1 Patients

Nine of the 11 patients have required one or more intubations. All were intubated in respiratory failure with oxygen requirement and were managed conventionally with respect to hydration and nutrition via feeding tubes, but not with respect to respiratory care (Table 1). Because oxygen administration can mask oxyhemoglobin desaturations that would otherwise signal airway mucus accumulation or hypoventilation, its use was restricted to patients who were acutely ill and intubated or who required emergency resuscitation.

Immediately upon extubation the patients received nasal ventilation with positive end-expiratory pressure at a rate slightly greater than the patients' spontaneous breathing rate. This was provided by a ventilator support system (BiPAP-ST; Respironics Inc; Murrysville, PA) for 10 children, and by volume-cycled ventiliator (Bird VIP; Exeter, UK) on assist/control for one patient who breathed more rapidly than the maximum rate of the BiPAP device. Initially, an inspiratory positive airway pressure (IPAP) of 10 cm [H.sub.2]O was used, but the IPAP was quickly increased to 20 cm [H.sub.2]O, or to the point that the patient demonstrated good chest expansion and the spontaneous respiratory rate slowed. Thus, although the small infants could not trigger the BiPAP-ST, provided that IPAP/EPAP (expiratory positive airway pressure) spans were adequate, they breathed in synchrony with it unless their spontaneous rate exceeded the machine's capabilities. The EPAP was 3 cm [H.sub.2]O. An EPAP of 3 cm [H.sub.2]O was used to prevent excessive [CO.sub.2] rebreathing, while minimizing any decrease in the IPAP/EPAP span.[10]

All patients were eventually weaned to nocturnal only nasal ventilation and were discharged using a BiPAP-ST. After discharge, daytime end-tidal [CO.sub.2] remained normal for all patients. Bilevel spans were adjusted during sleep to achieve good chest expansion during inspiration and all Sa[O.sub.2] level of 94% without supplemental oxygen, and to better rest inspiratory muscles. All children received IPAP [is greater than] 14 cm [H.sub.2]O.

We often used modified Hudson size 4 or 5 infant nasal continuous positive airway pressure cannulas (Hudson Respiratory Care; Temecula, CA) as nasal interfaces (Fig 1). The nasal seal had to be adequate for the infants to trigger or synchronize with the ventilator; otherwise, they often experienced precipitous oxyhemoglobin desaturations that necessitated brief manual resuscitation. The nasal interface was connected to the ventilator circuit using intervening tubing adapters. The restraints for these prongs were originally designed for infants weighing 2, kg; therefore, they had to be improvised (Fig 1). For our children between 6 months and 5 years of age, when tolerated and effective (with minimal leak), we used the Respironics (Murrysville, PA) pediatric nasal mask.


While nasal ventilation aided inspiratory muscle function, expiratory aid was provided by manual abdominal compressions during the exsufflation phase of mechanical insufflation-exsufflation (MI-E). MI-E was used via indwelling tubes or, after extubation, was provided via oral-nasal interfaces.[11] Manual thrusts were not performed or were performed gingerly for 2 h after meals.

The caregivers were trained in all aspects of noninvasive support as well as in chest percussion and postural drainage. They provided the bulk of the care within hours of extubation and through discharge. The children were discharged home with pulse oximeters, in-exsufflators (J.H. Emerson Co; Cambridge, MA), and BiPAP-ST machines. After initial hospitalization, arrangements were made for 24-h nursing for 1 week. The home nurses were trained by specifically trained respiratory therapists and ultimately by the parents. Patients were considered able to cooperate successfully with the protocol when they could avoid hospitalizations despite requiring continuous nasal ventilation and despite having airway mucus-associated oxyhemoglobin desaturations reversed by using respiratory muscle aids.[9] This was usually the case by 4 years of age. The patients presented for physician evaluation when Sa[O.sub.2] decreased [is less than] 95% despite use of nasal ventilation and expiratory support, when fever persisted, or when dehydration was suspected.

We defined a failed extubation as that resulting in reintubation during the same hospitalization. We used a contingency table with Instat Software (Graphpad; San Diego, CA) and developed an odds-for-success ratio for protocol vs nonprotocol extubations using the Woolf approximation.[12] The two-tailed Fisher's Exact t Test for unpaired data was used to determine significance. A p value 0.05 was considered significant.


In all, 11 consecutively referred patients were treated by the respiratory aid protocol. The demographic data and the results of management are summarized in Table 2. They had 28 distinct episodes of respiratory compromise necessitating hospitalizations: 2 postoperative, 2 associated with insidiously progressive inspiratory muscle dysfunction, and 24 sudden episodes mostly due to chest colds. These resulted in a total of 48 intubations. Nonprotocol therapy and extubation were attempted 20 times, including 8 times at our institution by nonparticipating physicians. Protocol therapy was used 28 times. On 9 occasions children were extubated to continuous nasal ventilation despite having no autonomous breathing capability. These patients weaned to nocturnal-only nasal ventilation up to 3 weeks after extubation. In three cases, the infants weaned to nocturnal-only nasal ventilation after discharge home. Two patients (Table 2, patients 10 and 11) remained 24-h ventilator dependent.

(*) Age a = first diagnosed;

age b = first intubation or episode requiring ventilatory support;

age c = last follow up;

ages c-b = except for patient nos. 6 and 8, months of use of nocturnal nasal ventilation.

M = male;

F = female.

([dagger]) Lost to follow-up.

([double dagger]) Deceased suddenly after 3 months of tracheostomy ventilation.

([sections]) Underwent tracheostomy following an unsuccessful extubation using the protocol.

Protocol care was generally well tolerated, although two children had periods of abdominal distention while using nasal ventilation and required frequent burping of gastrostomy tubes. MI-E expulsed the secretions into the endotracheal tube or adapter or the mouth, from where they were suctioned, and oxyhemoglobin desaturations were reversed. Two patients received IM glycopyrrolate to decrease secretions before extubation.

Comparing the success of protocol vs nonprotocol extubations, the two-tailed Fisher's Exact t Test p value of 0.001 was very significant. The odds ratio was 18.72, with a confidence interval from 2.85 to 92.56.[12]

One child (patient 6) succeeded in being extubated and discharged home with normal Sa[O.sub.2] and using only nocturnal nasal ventilation but was rehospitalized in respiratory failure three times in 5 months because of persistent left lung collapse. She underwent tracheostomy and used nocturnal tracheostomy ventilation but died suddenly, at home, 3 months later. Another patient who developed respiratory failure at only 3 months of age (Table 2, patient 8) underwent tracheostomy at 7 months of age, after six intubations during 3 months of almost continuous hospitalization. Another patient (patient 2) was lost to follow-up subsequent to relocation 3 months after successful extubation. The other seven patients are alive a mean of 34.7 months since their first episodes of respiratory failure. This includes one 6-year-old boy who has been hospitalized and intubated six times during intercurrent chest colds. Over the last 2 years, however, he has required continuous nasal ventilation and has successfully reversed airway mucus-associated oxyhemoglobin desaturations during four chest colds, thereby avoiding several hospitalizations.[9] Two children have required continuous nasal ventilation and have had no autonomous breathing ability for 59 and 32 months, respectively, without ever being intubated. Although we do not have the hospital length of stay data for the patients managed at other institutions, the mean number of days our protocol patients were intubated was 8.2 [+ or -] 3.2, and the mean hospital stay was 16.6 [+ or -] 7.8 days.

Untreated SMA type 1 children have paradoxical breathing and develop pectus excavatum that worsens with time. Pectus excavatum disappeared with institution of nocturnal nasal ventilation for all 11 children.


This study suggests that it may be possible for infants with SMA type 1 to avoid tracheostomy long enough to be able to cooperate with the use of respiratory muscle aids and possibly safely avoid tracheostomy indefinitely.[6,9] This is important because the parents of children with neuromuscular disease often refuse tracheostomy but want their children to survive.

Hypercapnia can cause oxyhemoglobin desaturation. We have noted that patients with neuromuscular disease tend to become symptomatic for hypercapnia only when it causes Sa[O.sub.2] to decrease [is less than] 95%. Likewise, desaturation can be caused by accumulating airway mucus. Thus, oxygen administration can eliminate oximetry as an important monitor of airway plugging and clinically significant alveolar hypoventilation, and it can result in exacerbation of hypercapnia. It was only used after extubation in conjunction with manual resuscitation to treat precipitous desaturations as nasal interfaces were being fit, ventilator synchronization achieved, and airway secretions exsufflated and suctioned. Its avoidance played an important role in the success of this protocol.

The use of nasal ventilation was reported to have failed to prolong life for children with SMA type 1.[3] However, in this latter attempt, the low bilevel spans used may not have been adequate, and MI-E was not used. All four patients who died did so from inadequate ventilatory assistance or from failure to intubate or use expiratory aids during chest colds once the parents were resigned to let their children die.[3] Indeed, MI-E via an indwelling tube has never before been reported. However, whether via a tube or via the upper airway, its use succeeded in eliminating airway mucus, and the children showed neither discomfort nor any evidence of barotrauma. It is also appropriate for SMA type 1 children to nocturnally use high span bilevel positive airway pressure to prevent pectus excavatum and to promote more normal lung growth.

Shortcomings of this study include the small number of patients due to the rarity of this condition, and the lack of controls. However, performing a randomized, controlled trial in adequate numbers would be extremely difficult, if not impossible, considering the sporadic occurrence of the disease, and the ethical issues involved in getting parents to permit such a trial. We excluded SMA type 2 patients to maintain sample homogeneity and because SMA type 2 patients are much easier to manage by this protocol. Despite the small population, however, these 11 children had 48 interventions.

It might also be argued that a selection bias existed. Patients who repeatedly succeed in being extubated with conventional care might not have been referred to us, and this might have resulted in children surviving without tracheostomy and without the use of our protocol. However, 3-year survival has not been reported for children with SMA type 1 without tracheostomy, and only one other center has reported 24-h ventilator users (none with SMA type 1), managed strictly noninvasively.[13] Thus, most of the seven SMA type 1 infants known to be managed noninvasively and who now have a mean age of 43.4 months would have been expected to have died or undergone tracheostomy by this time.

Larger issues at hand are those of quality of life, cost, and survival comparisons with children ventilated via tracheostomies. Tracheostomy intermittent positive pressure ventilation has occasionally permitted children with SMA type 1 to survive more than 4 years.[14] While "do not resuscitate" orders may be an acceptable alternative to tracheostomy for some parents, noninvasive ventilation can prolong life,[6] is more desirable than tracheostomy,[15] and, in our experience has not been refused. Patients who have used both tracheostomy and noninvasive ventilatory support almost invariably prefer the latter for safety, convenience, and facilitation of speech, sleep, swallowing, appearance, comfort, and overall acceptability.[16] Besides the disadvantages of tracheostomy ventilation,[6,9] the imposition of a tube often results in the need for continuous, rather than nocturnal-only ventilator use.[16] This, along with need for tracheal suctioning, has untoward consequences on quality of life.[17] Further, considering the ethics of ventilator use, unlike for tracheostomy ventilation users, individuals using noninvasive aids can discontinue them on their own.

On the other hand, the introduction of noninvasive ventilation often requires effort intensive ventilator synchronization, interface preparation and fitting, and airway secretion management, especially when the patient cannot cooperate. Thus, after extubation, patients can require close surveillance and intensive intervention for days until they wean to nocturnal-only nasal ventilation and their airway secretions have dissipated. The first few hours after extubation can require the continuous presence and intense efforts of a highly skilled respiratory therapist to manage sudden, precipitous oxyhemoglobin desaturations. Because it can be virtually impossible to achieve this level of ongoing respiratory-nursing care for more than the initial few post-extubation hours in our understaffed intensive care units, we train the infants' parents and rely heavily on them to eventually provide much if not most of the intensive care. Having a thoroughly trained and totally dedicated family member or care provider is critical for successful noninvasive home management. It must be emphasized that the parent must be comfortable managing sudden oxyhemoglobin desaturations by manually resuscitating the patient, using MI-E and oral suctioning, re-adjusting nasal interfaces, repositioning, and applying other therapies to facilitate lung ventilation and airway secretion elimination. It is unlikely that this approach can succeed long-term in the event that both parents work or have difficulty learning or performing the interventions required. Both of our patients who underwent tracheostomy had supoptimal parent involvement.

Cost is a difficult issue. For patients with milder neuromuscular conditions, such as Duchenne muscular dystrophy, the avoidance of respiratory complications and hospitalizations with the use of noninvasive respiratory muscle aids create considerable cost savings by comparison with the multiple and often prolonged hospitalizations associated with conventional management and tracheostomy.[1,9,18] However, at least until SMA patients are old enough to cooperate with the noninvasive protocol, essentially every chest cold must be treated by hospitalization and intubation. This may be more costly and effort-intensive than managing intercurrent chest colds via a tracheostomy tube. Cost, quality of life, and survival issues deserve further study.

In summary, the need to intubate an SMA type 1 infant does not mean that tracheostomy is inevitable. These patients have a better chance of successful extubation when they are extubated in the manner used in this study. Although intubation may be required during intercurrent chest colds, tracheostomy can usually be avoided if respiratory muscle aids are used by highly trained and dedicated parents in both the acute and home settings, as needed.

ACKNOWLEDGMENT: We thank the University Hospital respiratory therapists, nurses, patients, and their parents, without whose support this study would not have been possible.


[1] Brooke MH. A clinician's view of neuromuscular diseases. 2nd ed. 2. Baltimore, MD: Williams & Wilkins, 1986; 243-331

[2] Zerres K, Rudnik-Schoneborn S. Natural history in proximal spinal muscular atrophy: clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol 1995; 52:518-523

[3] Birnkrant DJ, Pope JF, Martin JE, et al. Treatment of type 1 spinal muscular atrophy with noninvasive ventilation and gastrostomy feeding. Pediatr Neurol 1998; 18:407-410

[4] Wysocki M, Tric L, Wolff MA, et al. Noninvasive pressure support ventilation in patients with acute respiratory failure. Chest 1993; 103:907-913

[5] Antonelli M, Conti G, Rocco M, et al. A comparison of noninvasive positive pressure ventilation and conventional mechanical ventilation in patients with acute respiratory failure. N Engl J Med 1998; 339:429-435

[6] Bach JR, Rajaraman R, Ballanger F, et al. Neuromuscular ventilatory insufficiency: the effect of home mechanical ventilator use vs. oxygen therapy on pneumonia and hospitalization rates. Am J Phys Med Rehabil 1998; 77:8-19

[7] Bach JR, Alba AS, Saporito LR. Intermittent positive pressure ventilation via the mouth as an alternative to tracheostomy for 257 ventilator users. Chest 1993; 103:174-182

[8] Bach JR, Alba AS. Management of chronic alveolar hypoventilation by nasal ventilation. Chest 1990; 97:52-57

[9] Bach JR, Ishikawa Y, Kim H. Prevention of pulmonary morbidity for patients with Duchenne muscular dystrophy. Chest 1997; 112:1024-1028

[10] Kacmarek RM. Characteristics of pressure-targeted ventilators used for noninvasive positive pressure ventilation. Respir Care 1997; 42:380-388

[11] Bach JR. Update and perspectives on noninvasive respiratory muscle aids: part 2-the expiratory muscle aids. Chest 1994; 105:1538-1544

[12] Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 1955; 19:251-253

[13] Viroslav J, Rosenblatt R, Morris-Tomazevic S. Respiratory management, survival, and quality of life for high-level traumatic tetraplegics. Respir Clin North Am 1996; 2:313-322

[14] Wang TG, Bach JR, Avilez C, et al. Survival of individuals with spinal muscular atrophy on ventilatory support. Am J Phys Med Rehabil 1994; 73:207-211

[15] Bach JR. A comparison of long-term ventilatory support alternatives from the perspective of the patient and care giver. Chest 1993; 104:1702-1706

[16] Haber II, Bach JR. Normalization of blood carbon dioxide levels by transition from conventional ventilatory support to noninvasive inspiratory aids. Arch Phys Med Rehabil 1994; 75:1145-1150

[17] Bach JR. Ventilator use by muscular dystrophy association patients: an update. Arch Phys Med Rehabil 1992; 73:179-183

[18] Bach JR, Intintola P, Alba AS, et al. The ventilator-assisted individual: cost analysis of institutionalization versus rehabilitation and in-home management. Chest 1992; 101:26-30

(*) From the Department of Physical Medicine and Rehabilitation (Dr. Bach), the Department of Pediatrics (Dr. Niranjan), University of Medicine and Dentistry of New Jersey-New Jersey Medical School; and University Hospital (Mr. Weaver), Newark, NJ.

This work was performed at the University Hospital of the University of Medicine and Dentistry of New Jersey-New Jersey Medical School in Newark, NJ.

Manuscript received February 8, 1999; revision accepted October 26, 1999.

Correspondence to: John R. Bach, MD, FCCP, Department of Physical Medicine and Rehabilitation, University Hospital B-403, 1,50 Bergen Street, Newark, NJ 07103; e-mail:

COPYRIGHT 2000 American College of Chest Physicians
COPYRIGHT 2000 Gale Group

Return to Multiple system atrophy
Home Contact Resources Exchange Links ebay